ReviewZhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery2026
[Application and challenges of tissue engineered scaffolds in treatment of long-segment laryngotracheal stenosis].
Review in Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the application and research progress of tissue-engineered scaffolds in the treatment of long-segment laryngotracheal stenosis (LTS). Methods: A comprehensive review of relevant domestic and international literature was conducted to summarize and analyze the application of different tissue-engineered scaffolds in the treatment of long-segment LTS, including the use of natural materials, synthetic polymers, their composite materials, and biodegradable metals. Results: Conventional treatment methods for long-segment LTS are often limited in efficacy and associated with a high risk of complications. Tissue-engineered scaffolds can simulate the extracellular matrix and provide a suitable microenvironment for cellular growth, effectively supporting and promoting the repair and regeneration of laryngotracheal tissues. However, different scaffold materials exhibit distinct characteristics in terms of performance and clinical application. Natural materials offer good biocompatibility but insufficient mechanical strength and overly rapid degradation; synthetic polymers provide tunable mechanics but weak bioactivity and a tendency to induce inflammation; composite materials integrate the advantages of both, combining bioactivity with structural strength; biodegradable metal stents possess high mechanical strength and favorable degradability, but optimization of corrosion rate and the safety of degradation products is still required. Conclusion: Tissue-engineered scaffolds offer a novel therapeutic approach for long-segment LTS. However, further research and optimization of scaffold materials and design are required to enhance treatment efficacy and clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.